Skip to main content

What the FDA labels say about taking them together

Ivacaftor/lumacaftor and repaglinide

Ivacaftor/lumacaftor's FDA label of March 24, 2026 names repaglinide in its drug interactions section; the repaglinide label PlainMeds reads does not name ivacaftor/lumacaftor. The ivacaftor/lumacaftor label: “Concomitant use of ORKAMBI may reduce the exposure and effectiveness of repaglinide and may alter the exposure of sulfonylurea.”

Check it at the source: the ivacaftor/lumacaftor FDA label on DailyMed (effective March 24, 2026, Vertex Pharmaceuticals Incorporated); the repaglinide FDA label on DailyMed (effective May 2, 2025, Chartwell RX, LLC).

What does the ivacaftor/lumacaftor label say about repaglinide?

Ivacaftor/lumacaftor label, drug interactions

Concomitant use of ORKAMBI may reduce the exposure and effectiveness of repaglinide and may alter the exposure of sulfonylurea.

Source: FDA drug label (ORKAMBI), Vertex Pharmaceuticals Incorporated, effective March 24, 2026 (SPL set 3fc1c40e-cfac-47a1-9e1a-61ead3570600), via openFDA; the full label on DailyMed

What does the repaglinide label say about ivacaftor/lumacaftor?

Repaglinide's label (effective May 2, 2025) does not name ivacaftor/lumacaftor in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Repaglinide), Chartwell RX, LLC, effective May 2, 2025 (SPL set cb995e92-295e-4638-a064-978211f5afe1), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Ivacaftor/lumacaftor generic labelers
7Repaglinide generic labelers
Ivacaftor/lumacaftorRepaglinide
Labeled forn/aType 2 diabetes
Boxed warningNoNo
Pharmacy cost (NADAC)n/a$0.0987 per tablet 1 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?